Thomas A. MCCOURT

Insider Reports History

Entity
Individual
Location
C/O Ironwood Pharmaceuticals, Inc., 100 Summer Street, Suite 2300, Boston, MA
Signature
/s/ Mike Ouimette, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Thomas A. MCCOURT:

Stock Role Class Num Shares Value Price $ Report Date Ownership
IRONWOOD PHARMACEUTICALS INC Chief Executive Officer, Director Class A Common Stock 1.15M $7.42M $6.45 May 20, 2024 Direct
PLIANT THERAPEUTICS, INC. Director Common Stock (Right to Buy) 26.8K $55.7K $2.08 Jun 13, 2024 Direct
IRONWOOD PHARMACEUTICALS INC Chief Executive Officer, Director Performance-based Restricted Stock Unit 0 $0 $8.70 Mar 8, 2024 Direct
ACCELERON PHARMA INC Director Common Stock 0 $29.37 Nov 19, 2021 Direct
ACCELERON PHARMA INC Director Option to Purchase Common Stock 0 Nov 19, 2021 Direct

Insider Reports Filed by Thomas A. MCCOURT

Symbol Company Period Transactions Value $ Form Type Date Filed Role
PLRX PLIANT THERAPEUTICS, INC. Jun 13, 2024 1 $0 4 Jun 17, 2024 Director
IRWD IRONWOOD PHARMACEUTICALS INC May 20, 2024 1 -$436K 4 May 22, 2024 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Mar 8, 2024 2 $0 4 Mar 12, 2024 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Mar 5, 2024 2 $0 4 Mar 7, 2024 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Feb 12, 2024 1 -$2.7M 4 Feb 14, 2024 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Jan 17, 2024 1 $0 4 Jan 19, 2024 Chief Executive Officer, Director
PLRX PLIANT THERAPEUTICS, INC. Jun 7, 2023 1 $0 4 Jun 8, 2023 Director
IRWD IRONWOOD PHARMACEUTICALS INC May 30, 2023 1 -$285K 4 Jun 1, 2023 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC May 22, 2023 1 -$364K 4 May 24, 2023 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC May 8, 2023 1 -$225K 4 May 10, 2023 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Mar 27, 2023 1 -$492K 4 Mar 29, 2023 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Mar 8, 2023 2 $0 4 Mar 10, 2023 Chief Executive Officer, Director
PLRX PLIANT THERAPEUTICS, INC. Mar 6, 2023 1 $0 4 Mar 8, 2023 Director
PLRX PLIANT THERAPEUTICS, INC. Mar 6, 2023 0 $0 3 Mar 8, 2023 Director
IRWD IRONWOOD PHARMACEUTICALS INC Mar 3, 2023 1 -$379K 4 Mar 7, 2023 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Feb 27, 2023 4 -$696K 4 Mar 1, 2023 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Jan 17, 2023 1 $0 4 Jan 19, 2023 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Jan 5, 2023 3 -$46.6K 4 Jan 9, 2023 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Oct 3, 2022 1 -$197K 4 Oct 5, 2022 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Sep 1, 2022 1 -$282K 4 Sep 6, 2022 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Aug 1, 2022 1 -$264K 4 Aug 3, 2022 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Jun 30, 2022 1 -$231K 4 Jul 5, 2022 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC May 23, 2022 3 -$418K 4 May 25, 2022 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Mar 8, 2022 1 $0 4 Mar 10, 2022 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Feb 28, 2022 4 -$522K 4 Mar 2, 2022 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Jan 19, 2022 1 $0 4 Jan 21, 2022 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Dec 22, 2021 1 -$529K 4 Dec 23, 2021 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC Nov 23, 2021 1 -$610K 4 Nov 24, 2021 Chief Executive Officer, Director
XLRN ACCELERON PHARMA INC Nov 19, 2021 4 $0 4 Nov 22, 2021 Director
IRWD IRONWOOD PHARMACEUTICALS INC Jun 7, 2021 1 $0 4 Jun 9, 2021 Chief Executive Officer, Director
IRWD IRONWOOD PHARMACEUTICALS INC May 24, 2021 1 -$21K 4 May 26, 2021 President and Interim CEO